Abstract

Sickle cell disease (SCD) is an inherited hemoglobinopathy with an increased risk of neurological complications. Due to anemia and other factors related to the underlying hemoglobinopathy, cerebral blood flow (CBF) increases as compensation; however, the nature of alterations in oxygen extraction fraction (OEF) and cerebral metabolic rate of oxygen (CMRO2) in SCD remains controversial, largely attributed to the different calibration models. In addition, limited studies have been done to investigate oxygen metabolism in pediatric patients. Thus, this study used a non-invasive T2-based MR oximetry, T2-Relaxation-Under-Spin-Tagging (TRUST) MRI, to measure oxygen homeostasis in pediatric patients with SCD using four different calibration models and examined its relationship to hematological measures. It was found that, compared with controls, SCD patients showed an increased CBF, unchanged total oxygen delivery and increased venous blood T2. The results of OEF and CMRO2 were dependent on the calibration models used. When using sickle-specific, hemoglobin S (HbS) level-dependent calibration, there was a decreased OEF and CMRO2, while the bovine model showed an opposite result. OEF and CMRO2 were also associated with hemoglobin and HbS level; the direction of the relationship was again dependent on the model. Future studies with in vivo calibration are needed to provide more accurate information on the T2-Yv relationship.

Highlights

  • Sickle cell disease (SCD) is an inherited blood disorder, in which a beta globin gene mutation causes the formation of a mutated protein, hemoglobin S (HbS), leading to the deformation of red blood cell (RBC) into a sickled shape

  • This leads to hemolysis and decreased hemoglobin, decreased arterial oxygen content, resulting in an elevated cerebral blood flow (CBF) in order to compensate for the oxygen demand of the brain (Herold et al, 1986; Hurlet-Jensen et al, 1994a; Li et al, 2020)

  • Sickle cell disease participants had a significantly higher venous T2 compared with control participants (SCD: 91.2 ± 13.4 ms, control: 72.0 ± 9.6 ms, p = 0.0033, Table 2)

Read more

Summary

Introduction

Sickle cell disease (SCD) is an inherited blood disorder, in which a beta globin gene mutation causes the formation of a mutated protein, hemoglobin S (HbS), leading to the deformation of red blood cell (RBC) into a sickled shape. This leads to hemolysis and decreased hemoglobin, decreased arterial oxygen content, resulting in an elevated cerebral blood flow (CBF) in order to compensate for the oxygen demand of the brain (Herold et al, 1986; Hurlet-Jensen et al, 1994a; Li et al, 2020). A disease modifying treatment for SCD, is associated with lower CBF and OEF (Guilliams et al, 2018)

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call